New identity reflects enhanced service offering, innovation capacity, and operational scale through full integration with Ricoh Group.
Baltimore, MD – July 15, 2025 – Elixirgen Scientific, Inc., a pioneer in induced pluripotent stem (iPS) cell technology and messenger RNA (mRNA) drug development, today announced its rebrand to Ricoh Biosciences Inc., effective immediately. The change marks a major milestone following the company’s full acquisition by Ricoh Company, Ltd. in March 2025, and signals a bold step forward in building a unified, global biomedical innovation platform.
The rebrand reflects the company’s evolution into a more fully integrated drug discovery and development partner offering broader capabilities, enhanced technologies, and greater scalability to better serve its pharmaceutical partners, research collaborators, and clients around the world.
Strengthened Capabilities, Global Support
As a wholly owned subsidiary of Ricoh since 2022, the company has leveraged Ricoh’s expertise in advanced manufacturing, process automation, and quality control to significantly enhance its core offerings:
- iPS Cell Solutions: Advanced differentiation technologies to streamline target discovery, disease modeling, and screening workflows for pharmaceutical partners.
- mRNA CDMO Services: Scalable, high-quality design, and manufacturing of mRNA-based vaccines and therapeutics tailored to pharmaceutical partner needs.
“Our rebrand to Ricoh Biosciences represents more than a new name; it signals a transformation in how we serve our partners,” said Dr. Keiki Sugimoto, Chief Executive Officer of Ricoh Biosciences Inc. “As part of the Ricoh Group, we now offer a rare combination of scientific innovation and industrial-grade manufacturing that enables faster, more efficient therapeutic development from concept to clinic.”
Accelerating Discovery in Key Therapeutic Areas
Ricoh Biosciences will continue advancing its Quick-Tissue™ platform, enabling rapid, high-quality differentiation of iPS and embryonic stem (ES) cells for pharmaceutical research and preclinical testing. The platform supports partners’ efforts in tackling high-impact diseases, including neurodegenerative conditions, metabolic and inflammatory diseases.
Its mRNA CDMO capabilities position the company as a key enabler in the next generation of vaccines and RNA-based therapeutics, with full-spectrum support from construct design through GMP production.
Seamless Continuity for Clients and Collaborators
Current partners and customers will experience no disruption in services or agreements. All existing contracts, collaborations, and service terms will remain in full effect under the Ricoh Biosciences brand. The company’s ISO 9001 certification, commitment to quality, and customer support processes remain unchanged.
“This transition is designed to benefit our partners—from faster timelines and expanded R&D capabilities to the support of a global infrastructure,” said Dr. Sugimoto. “We remain committed to being a flexible, science-driven partner at every stage of your discovery and development journey.”
Built for Global Growth and Scientific Impact
Ricoh Biosciences will continue to operate from its Baltimore headquarters while expanding operations in Japan and beyond through Ricoh’s global network. The rebrand also aligns with Ricoh Group’s commitment to solving global challenges, such as population aging and pandemic preparedness, through socially impactful business innovation.
Looking Ahead
Ricoh Biosciences is actively investing in new technologies, expanding its service offerings, and pursuing strategic partnerships to unlock new possibilities in cellular and RNA-based therapeutics. The company’s recognition as a Top 10 APAC CDMO and finalist at the 2024 Citeline Awards highlights its growing role as a trusted partner in the life sciences ecosystem.
About Ricoh Biosciences Inc.
Ricoh Biosciences Inc., formerly Elixirgen Scientific, is a biotechnology company specializing in iPS cell-based research tools and mRNA drug development services. Through its proprietary Quick-Tissue™ technology and full-service mRNA CDMO capabilities, Ricoh Biosciences supports pharmaceutical and biotech partners in accelerating discovery and development. Headquartered in Baltimore, Maryland, the company operates as a wholly owned subsidiary of Ricoh Company, Ltd. Learn more at www.biosciences.ricoh.com (transitioning from www.elixirgensci.com).
About Ricoh
Ricoh is a leading provider of integrated digital services and print and imaging solutions designed to support digital transformation of workplaces, workspaces and optimize business performance. Headquartered in Tokyo, Ricoh’s global operation reaches customers in approximately 200 countries and regions, supported by cultivated knowledge, technologies, and organizational capabilities nurtured over its 85-year history. In the financial year ended March 2024, Ricoh Group had worldwide sales of 2,348 billion yen (approx. 15.5 billion USD). It is Ricoh’s mission and vision to empower individuals to find Fulfillment through Work by understanding and transforming how people work so we can unleash their potential and creativity to realize a sustainable future. For further information, please visit www.ricoh.com.
Media Contact:
Ricoh Biosciences, Inc.
Phone: (443) 869-5420
Email: info@biosciences.ricoh.com